PIM1 Kinase as a Target in Prostate Cancer: Roles in Tumorigenesis, Castration Resistance, and Docetaxel Resistance

E-ISSN： 1873-5576|14|2|105-114

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.14, Iss.2, 2014-02, pp. : 105-114

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PIM1 kinase as a target for cancer therapy

By Merkel Anna Lena Meggers Eric Ocker Matthias

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 4, 2012-04 ,pp. : 425-436

Informa Healthcare

Access to resources Recommend Favorite

Cholesterol as a Potential Target for Castration-Resistant Prostate Cancer

By Twiddy Alexis Leon Carlos Wasan Kishor

Pharmaceutical Research, Vol. 28, Iss. 3, 2011-03 ,pp. : 423-437

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients

Cancer, Vol. 120, Iss. 24, 2014-12 ,pp. : 3923-3931

Blackwell Publishing

Access to resources Recommend Favorite

Docetaxel: A Review of its Use for the First-Line Treatment of Advanced Castration-Resistant Prostate Cancer

By McKeage Kate

Drugs, Vol. 72, Iss. 11, 2012-07 ,pp. : 1559-1577

Adis International

Access to resources Recommend Favorite

Overcoming Drug Resistance and Treating Advanced Prostate Cancer

Current Drug Targets, Vol. 13, Iss. 10, 2012-09 ,pp. : 1308-1323

Bentham Science Publishers

Access to resources Recommend Favorite